Nuparp Rucaparib 300 mg Tablet
Nuparp Rucaparib 300 mg Tablet is an advanced targeted anti-cancer medication containing Rucaparib as its active ingredient. It belongs to a class of drugs known as PARP (Poly ADP-Ribose Polymerase) inhibitors, which are used in the treatment of certain cancers, especially ovarian, fallopian tube, and primary peritoneal cancers.
Rucaparib works by blocking the PARP enzyme that helps repair damaged DNA in cancer cells. By inhibiting this repair mechanism, it causes cancer cells—particularly those with BRCA gene mutations—to die, slowing or stopping tumor growth. This targeted therapy is widely used when cancer has returned after chemotherapy or as maintenance therapy.
📞 Contact Details to Place Order
💬 WhatsApp: +91 9730316395
📞 Phone: +91 9730316395
📧 Email: info@globmedindia.com
🌐 Website: https://globmedindia.com
Composition and Content
- Active Ingredient: Rucaparib 300 mg
- Form: Oral Tablet
- Class: PARP Inhibitor (Targeted Therapy)
- Packaging: Typically available in blister packs or bottles (as per manufacturer)
How to Use
- Take the tablet orally with or without food, as prescribed by your oncologist.
- Swallow whole with water—do not crush or chew.
- Maintain a consistent schedule to ensure effectiveness.
- Continue treatment unless advised otherwise by your doctor.
Dosage
- The usual recommended dose is 600 mg twice daily (i.e., two 300 mg tablets in the morning and evening).
- Dose adjustments may be required based on:
- Side effects
- Liver or kidney function
- Patient response
⚠️ Always follow your doctor’s prescription—self-adjustment is not advised.
Uses
Nuparp Rucaparib 300 mg Tablet is primarily used for:
- Treatment of Ovarian Cancer
- Maintenance therapy in recurrent ovarian cancer
- Treatment of BRCA-mutated cancers
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Treatments & Mechanism
Rucaparib targets cancer cells by exploiting defects in DNA repair pathways:
- Blocks PARP enzyme activity
- Prevents repair of DNA damage
- Causes cancer cell death (synthetic lethality)
This makes it highly effective in patients with BRCA1/BRCA2 mutations.
Advantages
- ✔️ Targeted cancer therapy with higher precision
- ✔️ Oral administration (no hospital stay required)
- ✔️ Effective in recurrent cancers
- ✔️ Helps delay disease progression
- ✔️ Improves progression-free survival
Storage Conditions
- Store at room temperature (20°C–25°C)
- Keep away from moisture and direct sunlight
- Keep out of reach of children
- Do not use expired tablets
Alternative Indian Brands for Rucaparib
Some alternative brands (availability may vary in India):
- Generic Rucaparib Tablets (300 mg) by Indian pharmaceutical exporters
- Custom supply through oncology distributors like GlobMedIndia
- Other PARP inhibitors (alternative therapies):
- Olaparib
- Niraparib
(Consult your oncologist before switching medications.)
Buy Nuparp Rucaparib 300 mg Tablet Online – Fast Global Delivery by GlobMedIndia
Looking to buy Nuparp Rucaparib 300 mg Tablet online at the best price? GlobMedIndia is your trusted partner for high-quality anti-cancer medicines with fast, safe, and reliable international delivery.
We specialize in exporting oncology medicines to major locations across the United States of America including:
- California
- Washington
- Chicago
- Los Angeles
- Houston
- Phoenix
- Austin
- Columbus
- Philadelphia
- San Antonio
- San Diego
- Dallas
- Jacksonville
- Buy Rucaparib 300 mg online
- Nuparp Rucaparib price India
- PARP inhibitor tablets export
- Ovarian cancer targeted therapy medicine
- Affordable anti-cancer drugs India
- Rucaparib supplier USA delivery
- Oncology medicines exporter India
- BRCA mutation cancer treatment tablets
Why Choose GlobMedIndia?
- ✔️ Genuine & high-quality medicines
- ✔️ Competitive global pricing
- ✔️ Fast international shipping
- ✔️ Secure packaging & cold-chain support (if required)
- ✔️ Trusted exporter of life-saving drugs
🚀 Order Now
Get Nuparp Rucaparib 300 mg Tablet delivered safely to your doorstep. Contact us today for bulk or personal orders and experience seamless global healthcare access.
